In part 2 of our interview with Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine, we discuss the challenge inherent ...

The FDA has granted Priority Review to nipocalimab for the treatment of antibody positive patients with generalized myasthenia gravis.

UCB, a global biopharmaceutical company, today announced the CHMP (Committee for Medicinal Products for Human Use) has issued a positive opinion for the self-administration of RYSTIGGO® ...

Phase III Vivacity-MG3 trial shows that nipocalimab, an investigational FcRn blocker, significantly the improves symptoms of generalized myasthenia gravis with a manageable safety profile.

This SPA agreement marks an important milestone in the development of Descartes-08 for MG, providing critical regulatory clarity and a clear path toward potential approval,” said Carsten Brunn, Ph.D., ...

Medications for myasthenia gravis (MG ... and is approved for people who have tested positive for anti-acetylcholine receptor antibodies. Taking eculizumab may increase your risk for infections.

Myasthenia gravis (MG ... the disease is characterized by the presence of antibodies against the acetylcholine receptor, a protein found on the surface of nerve cells that plays a key role ...

Please provide your email address to receive an email when new articles are posted on . The FDA has granted priority review to a Biologics License Application for nipocalimab to treat individuals ...

Myasthenia gravis (MG) is a chronic autoimmune disorder that causes disabling muscle weakness and fatigue. For most people with MG, the disease is characterized by the presence of antibodies against ...

Myasthenia gravis occurs when the immune system has an abnormal response and produces a type of harmful antibody ... receptors are present for the binding of a neurotransmitter called ...